Compare SoundHound AI Inc (SOUN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs TG Therapeutics Inc — how do they compare? SoundHound AI Inc trades at $5.39 (market cap $2.45B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.3× SoundHound AI Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SoundHound AI Inc for 23 Days and TG Therapeutics Inc for 16 Days on average.
| SOUN | TGTX | |
|---|---|---|
Market Cap | $2.45B | $8.16B |
Volume | 16,881,989 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $21.40 | $59.06 |
52-Week Low | $5.52 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $2.25B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $5.39, down 4.26% on the day, with the stock showing bearish technical signals despite recent earnings beats. The company maintains strong revenue growth with 2026 projections at $203M but faces significant net losses (-$137M in 2026). Analyst sentiment remains positive with a 75% buy rating and $9.33 consensus price target, while recent news highlights expansion in automotive and restaurant voice AI deployments.
The stock presents a high-risk, high-reward opportunity with strong growth potential in voice AI markets but faces profitability challenges and negative cash flow trends. Key catalysts include continued revenue expansion and new product launches, while risks include integration challenges and persistent losses requiring careful monitoring of execution milestones.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
